Jorge Boczkowski

Jorge Boczkowski

Auto-generated profile, based on publicly available information

Jorge Boczkowski

INSERM, U955, Equipe 4, Créteil, F-94000, France

Research Focus & Metrics

Academic Career Length

56Years (1971-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Particle and Fibre Toxicology
Verified
Journal Article
Open access
PDF file
Sophie LanoneSophie Lanone
Sophie Lanone
FRFrançoise Rogerieux
Françoise Rogerieux
JGJorina Geys
Jorina Geys
ADAurélie Dupont
Aurélie Dupont
EMEmmanuelle Maillot-Marechal
Emmanuelle Maillot-Marechal
PHPeter H.M. Hoet
Peter H.M. Hoet
A critical issue with nanomaterials is the clear understanding of their potential toxicity. We evaluated the toxic effect of 24 nanoparticles of similar equivalent spherical diameter and various elemental compositions on 2 human pulmonary cell lines: A549 and THP-1. A secondary aim was to elaborate a generic experimental set-up that would allow the rapid screening of cytotoxic effect of nanoparticles. We therefore compared 2 cytotoxicity assays (MTT and Neutral Red) and analyzed 2 time points (3 and 24 hours) for each cell type and nanoparticle. When possible, TC50 (Toxic Concentration 50 i.e. nanoparticle concentration inducing 50% cell mortality) was calculated.

1 September 2006 in Current Molecular Medicine
Verified
Journal Article
Closed access
PDF file
Sophie LanoneSophie Lanone
Sophie Lanone
JBJorge Boczkowski
Jorge Boczkowski
Nanotechnologies, defined as techniques aimed to conceive, characterize and produce material at the nanometer scale, represent a fully expanding domain, and one can predict without risk that production and utilization of nanomaterials will increase exponentially in the coming years. Applications of nanotechnologies are numerous, in constant development, and their potential use in the medical field as diagnosis and therapeutics tools is very attractive. The size particularity of these nanomaterials gives them novel properties, allowing them to adopt new comportments because of the laws of quantum physics that exist at this scale. However, worries are expressed regarding the exact properties that make these nanomaterials attractive, and questions are raised regarding their potential toxicity, their long-term secondary effects or their biodegradability, particularly when thinking of their use in the (nano)medical field. These questions are justified by the knowledge of the toxic effects of atmospheric pollution micrometric particles on health, and the fear to get an amplification of these effects because of the size of the materials blamed. In this paper, we first expose the sensed medical applications of nanomaterials, and the physicochemical and molecular determinants potentially responsible for nanomaterials biological effects. Finally, we present a synthesis of the actual knowledge regarding toxicological effects of nanomaterials. It is clear that, in regard to the almost empty field of what is known on the subject, theres an urge to better understand biological effects of nanomaterials, which will allow their safe use, in particular in the nanomedicine field.

1 August 2010 in Thorax
Verified
Journal Article
Open access
PDF file
NANadia Amara
Nadia Amara
DGDelphine Goven
Delphine Goven
FPFabienne Prost
Fabienne Prost
RMRachel Muloway
Rachel Muloway
BCBruno Crestani
Bruno Crestani
JBJorge Boczkowski
Jorge Boczkowski
Background Persistence of myofibroblasts is believed to contribute to the development of fibrosis in idiopathic pulmonary fibrosis (IPF). Transforming growth factor β1 (TGFβ1) irreversibly converts fibroblasts into pathological myofibroblasts, which express smooth muscle α-actin (α-SMA) and produce extracellular matrix proteins, such as procollagen I (α1). Reactive oxygen species produced by NADPH oxidases (NOXs) have been shown to regulate cell differentiation. It was hypothesised that NOX could be expressed in parenchymal pulmonary fibroblasts and could mediate TGFβ1-stimulated conversion of fibroblasts into myofibroblasts. Methods Fibroblasts were cultured from the lung of nine controls and eight patients with IPF. NOX4, α-SMA and procollagen I (α1) mRNA and protein expression, reactive oxygen species production and Smad2/3 phosphorylation were quantified, in the absence and in the presence of incubation with TGFβ1. Migration of platelet-derived growth factor (PDGF)-induced fibroblasts was also assessed. Results It was found that (1) NOX4 mRNA and protein expression was upregulated in pulmonary fibroblasts from patients with IPF and correlated with mRNA expression of α-SMA and procollagen I (α1) mRNA; (2) TGFβ1 upregulated NOX4, α-SMA and procollagen I (α1) expression in control and IPF fibroblasts; (3) the change in α-SMA and procollagen I (α1) expression in response to TGFβ1 was inhibited by antioxidants and by a NOX4 small interfering RNA (siRNA); (4) NOX4 modulated α-SMA and procollagen I (α1) expression by controlling activation of Smad2/3; and (5) NOX4 modulated PDGF-induced fibroblast migration. Conclusion NOX4 is critical for modulation of the pulmonary myofibroblast phenotype in IPF, probably by modulating the response to TGFβ1 and PDGF.

1 April 2009 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
LSLaurent Savale
Laurent Savale
ACAri Chaouat
Ari Chaouat
SBSylvie Bastuji-Garin
Sylvie Bastuji-Garin
EMElisabeth Marcos
Elisabeth Marcos
LBLaurent Boyer
Laurent Boyer
SASerge Adnot
Serge Adnot
Rationale: Telomere length is considered a marker for biological aging. Chronic obstructive pulmonary disease (COPD) may be associated with premature aging. Objectives: To test the hypothesis that patients with COPD experience accelerated telomere shortening and that inflammation is linked to this process. Methods: We measured telomere length, using a quantitative polymerase chain reaction–based method, and plasma levels of various cytokines in 136 patients with COPD, 113 age- and sex-matched smokers, and 42 nonsmokers with normal lung function. Measurements and Main Results: Median (range) telomere length ratio was significantly lower in patients with COPD (0.57 [0.23–1.18]) than in control smokers (0.79 [0.34–1.58]) or nonsmokers (0.85 [0.38–1.55]) (P < 0.001). The difference remained highly significant when using logistic regression analysis adjusted for age, sex, and tobacco exposure. Both females and males with COPD had shorter telomere length than same-sex control subjects. Telomere length was related to age in patients and control subjects but was shorter in patients than in control subjects in all age groups. No relationship was found between telomere length and tobacco exposure in patients or control subjects, with no difference between control smokers and nonsmokers. In patients with COPD, telomere length was related to PaO2 (P < 0.001) and PaCO2 (P < 0.001) but not to lung function parameters or the BODE Index. Patients with COPD also had elevated plasma levels of various cytokines, interleukin-6 correlating negatively with telomere length (P < 0.001). Conclusions: Given that in vivo telomere length reflects cellular turnover and exposure to oxidative and inflammatory damage, our data support accelerated aging in COPD.

15 December 2011 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
VAValerie Amsellem
Valerie Amsellem
GGGuillaume Gary-Bobo
Guillaume Gary-Bobo
EMElisabeth Marcos
Elisabeth Marcos
BMBernard Maitre
Bernard Maitre
VCVicky Chaar
Vicky Chaar
SASerge Adnot
Serge Adnot
Rationale: Chronic obstructive pulmonary disease (COPD) is associated with chronic inflammation of unknown pathogenesis. Objectives: To investigate whether telomere dysfunction and senescence of pulmonary vascular endothelial cells (P-ECs) induce inflammation in COPD. Methods: Prospective comparison of patients with COPD and age- and sex-matched control smokers. Investigation of mice null for telomerase reverse transcriptase (Tert) or telomerase RNA component (Terc) genes. Measurements and Main Results: In situ lung specimen studies showed a higher percentage of senescent P-ECs stained for p16 and p21 in patients with COPD than in control subjects. Cultured P-ECs from patients with COPD exhibited early replicative senescence, with decreased cell-population doublings, a higher percentage of β-galactosidase–positive cells, reduced telomerase activity, shorter telomeres, and higher p16 and p21 mRNA levels at an early cell passage compared with control subjects. Senescent P-ECs released cytokines and mediators: the levels of IL-6, IL-8, monocyte chemotactic protein (MCP)-1, Hu-GRO, and soluble intercellular adhesion molecule (sICAM)-1 were elevated in the media of P-ECs from patients compared with control subjects at an early cell passage, in proportion to the senescent P-EC increase and telomere shortening. Up-regulation of MCP-1 and sICAM-1 led to increased monocyte adherence and migration. The elevated MCP-1, IL-8, Hu-GROα, and ICAM-1 levels measured in lungs from patients compared with control subjects correlated with P-EC senescence criteria and telomere length. In Tert−/− and/or Terc−/− mouse lungs, levels of the corresponding cytokines (MCP-1, IL-8, Hu-GROα, and ICAM-1) were also altered, despite the absence of external stimuli and in proportion to telomere dysfunction. Conclusions: Telomere dysfunction and premature P-EC senescence are major processes perpetuating lung inflammation in COPD.

29 August 2005 in The FASEB Journal
Verified
Journal Article
Closed access
PDF file
Sophie LanoneSophie Lanone
Sophie Lanone
SBSébastien Bloc
Sébastien Bloc
Roberta ForestiRoberta Foresti
Roberta Foresti
AAAbdelhamid Almolki
Abdelhamid Almolki
CTCamille Taillé
Camille Taillé
JBJorge Boczkowski
Jorge Boczkowski